1. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1
2. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates
3. 3 Boehringer Ingelheim Pharmaceuticals.Aptivus (Tipranavir) Prescribing Information. Ingelheim, Germany, Boehringer Ingelheim Pharmaceuticals.http://www.aptivus.com2006 .
4. 4 C Katlama, D Berger, and N Bellos et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials.12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 164LB].
5. 5 P Cahn, C Hicks, and for the RESIST-1 and RESIST-2 study teams. , RESIST-1 and RESIST-2 48 week meta-analyses demonstrate superiority of protease inhbitor (PI) tipranavir/ritonavir (TPV/r) over an optimised comparator PI (CPI/r) regimen in antiretroviral experienced patients.10th European AIDS Clinical Society Conference. Dublin, Ireland, November 2005 [Abstract LBPS3].